Multiple Sclerosis Medications|omicsgroup|Journal Of Multiple Sclerosis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Webinars & Conferences

Annual Summit on Neurological Disorders & Stroke

Webinar, Webinar

Multiple Sclerosis Medications

Multiple Sclerosis is an incurable disease which lacks a complete medication or a specific drug to the patient. “Medications used in MS are called Disease-Modifying Treatments (DMTs) since they do not stop the disease but only delay its activity and progression. DMTs have limited clinical efficacy and may have significant adverse effects. At present, we do not know what causes MS and, therefore, we cannot develop the MS cure” Balashov KE., Multiple Sclerosis: New Hypotheses Are Needed. Most of the multiple sclerosis medications are targeted on the reduction of relapses rather than the complete cure for associated symptoms. The first ever approved drug for this chronic acute demyelinating disease is interferon beta-1b in 1993. Most of these medications have unfavorable side effects that affect the patients. Journal of Multiple Sclerosis considers drug medications and related complications as one of the major issue of the journal. The journal is looking forward to present more articles based on this thus making the readers aware about the reliable medications.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on May, 2021